GSK Pays $430M Upfront for CureVac’s COVID-19, Flu mRNA Vaccines

GSK on Wednesday announced it is restructuring an existing collaboration agreement with German biotech CureVac, focusing on their investigational mRNA vaccines for influenza and COVID-19 while withdrawing from other infectious disease projects.